Bio Rad Labs Cl B (BIO.B) 151.40 $BIO.B Bio-Rad Reports

New Post Public Reply Private Reply Replies (0) Message Board

Sep 7, 2016 at 9:30 PM

Bio Rad Labs Cl B (BIO. 151.40 $BIO.B

Bio-Rad Reports Second-Quarter 2016 Financial Results
Marketwire Canada - Wed Aug 03, 3:18PM CDT
HERCULES, CA--(Marketwired - Aug 3, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2016.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market
Marketwired - Mon May 23, 7:30AM CDT
HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA).
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Bio-Rad posts 1Q profit
Automated Insights - Thu May 05, 4:12PM CDT
HERCULES, Calif. (AP) _ Bio-Rad Laboratories Inc. (BIO. on Thursday reported first-quarter profit of $12.3 million.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent
Marketwire Canada - Thu May 05, 3:16PM CDT
HERCULES, CA--(Marketwired - May 5, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, announced financial results today for the first quarter ended March 31, 2016.
BIO: 159.32 (+7.66), ILMN: 169.58 (-0.60), BIO.B: 151.40 (unch)

Bio-Rad Expands Its Cell Biology Portfolio With High Performance Flow Cytometer
Marketwired - Mon Feb 08, 3:30PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. and Propel Labs today announced that Bio-Rad has acquired a high performance analytical flow cytometer platform from Propel Labs that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. Bio-Rad expects to launch the instrument later this year.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Bio-Rad to Report Fourth-Quarter and Full-Year 2015 Financial Results Thursday, February 25, 2016
Marketwired - Tue Feb 02, 2:36PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, will report financial results fourth quarter and full year 2015 on Thursday, February 25, 2016, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Bio-Rad Joins Food Safety Consortium With IBM and Mars, Incorporated
Marketwired - Tue Jan 12, 8:30AM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it has joined the Consortium for Sequencing the Food Supply Chain established in 2015 by scientists from IBM Research (NYSE: IBM) and Mars, Incorporated. The consortium is combining advanced genomics with new informatics tools to observe microbial communities in food and detect hazards in the food supply chain that can threaten safety.
IBM: 161.64 (+1.29), BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Bio-Rad Named One of the 2015 Top 100 Bay Area Innovators by Thomson Reuters
Marketwired - Tue Jan 05, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it was named one of the "Thomson Reuters 2015 Top 100 Bay Area Innovators."
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Bio-Rad's TANGO infinity Receives FDA 510(k) Clearance for U.S. Markets
Marketwired - Mon Dec 21, 3:21PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance to market its TANGO infinity(R) system in the U.S. The system automates routine blood typing and screening testing procedures for patients and donors.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Bio-Rad Receives FDA Clearance for Its D-100 System for A1c Testing
Marketwired - Wed Dec 16, 5:19PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that its D-100(TM) System for A1c testing has obtained clearance from the U.S. Food and Drug Administration to monitor the long-term blood glucose control of individuals with diabetes, as an aid in the diagnosis of diabetes, and to help identify those who may be at risk for developing the disease.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Bio-Rad Reports Third-Quarter 2015 Financial Results
Marketwired - Tue Nov 03, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2015.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Bio-Rad to Report Third-Quarter 2015 Financial Results Tuesday, November 3, 2015
Marketwired - Mon Oct 19, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2015 on Tuesday, November 3, 2015, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Bio-Rad Introduces the IH-500, a Fully Automated Random Access System for Blood Typing and Screening
Marketwired - Mon Aug 03, 7:30AM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO., today announced the launch of the IH-500, a fully automated random access system for blood typing and screening, providing small and medium-size transfusion medicine laboratories fast and reliable results in a 24/7 environment. The IH-500 system is available in Europe, Asia, Africa, Australia, and Latin America.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Bio-Rad Announces U.S. FDA Pre-Market Approval for the BioPlex 2200 HIV Ag-Ab Assay, a Novel Next Generation HIV Diagnostic Test
Marketwired - Tue Jul 28, 3:15PM CDT
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO., a global provider of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration pre-market approval to offer its BioPlex(R) 2200 HIV Ag-Ab assay, the company's 5th generation HIV diagnostic test.
BIO: 159.32 (+7.66), BIO.B: 151.40 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Fuse Oncology Showcases New iRT Workflow at ASTRO

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Leo Cancer Care's Upright Radiotherapy Milestone

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

IASO's FUCASO Shows Robust Results in 2026 Study

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...